Hemabate 250 ug/mL

carboprost tromethamine · INJECTION, SOLUTION · Pharmacia & Upjohn Company LLC

No Recall History

Plain English

Hemabate is a injection, solution containing carboprost tromethamine at 250 ug/mL, taken intramuscular. Manufactured by Pharmacia & Upjohn Company LLC.

Key Facts

Brand Name: Hemabate
Generic Name: carboprost tromethamine
NDC Code (Product): 0009-0856
Manufacturer: Pharmacia & Upjohn Company LLC
Strength: 250 ug/mL
Dosage Form: INJECTION, SOLUTION
Route: INTRAMUSCULAR
Marketing Status
Application #: NDA017989
Marketing Start: 01/09/1979

Recall History

No Recall History

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

vomiting211 reports

nausea190 reports

off label use141 reports

diarrhoea135 reports

abdominal pain upper97 reports

chest discomfort89 reports

abdominal discomfort67 reports

abdominal pain64 reports

dyspnoea64 reports

blood pressure increased59 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE HEMABATE Sterile Solution is indicated for aborting pregnancy between the 13th and 20th weeks of gestation as calculated from the first day of the last normal menstrual period and in the following conditions related to second trimester abortion: 1. Failure of expulsion of the fetus during the course of treatment by another method; 2. Premature rupture of membranes in intrauterine methods with loss of drug and insufficient or absent uterine activity; 3. Requirement of a repeat intrauterine instillation of drug for expulsion of the fetus; 4. Inadvertent or spontaneous rupture of membranes in the presence of a previable fetus and absence of adequate activity for expulsion. HEMABATE is indicated for the treatment of postpartum hemorrhage due to uterine atony which has not responded to conventional methods of management. Prior treatment should include the use of intravenously administered oxytocin, manipulative techniques such as uterine massage and, unless contraindicated, intramuscular ergot preparations. Studies have shown that in such cases, the use of HEMABATE has resulted in satisfactory control of hemorrhage, although it is unclear whether or not ongoing or …

Dosage & Administration

DOSAGE AND ADMINISTRATION 1. Abortion and Indications 1–4 An initial dose of 1 mL of HEMABATE Sterile Solution (containing the equivalent of 250 micrograms of carboprost) is to be administered deep in the muscle with a tuberculin syringe. Subsequent doses of 250 micrograms should be administered at 1½ to 3½ hour intervals depending on uterine response. An optional test dose of 100 micrograms (0.4 mL) may be administered initially. The dose may be increased to 500 micrograms (2 mL) if uterine contractility is judged to be inadequate after several doses of 250 micrograms (1 mL). The total dose administered of carboprost tromethamine should not exceed 12 milligrams and continuous administration of the drug for more than two days is not recommended. 2. For Refractory Postpartum Uterine Bleeding An initial dose of 250 micrograms of HEMABATE Sterile Solution (1 mL of HEMABATE) is to be given deep, intramuscularly. In clinical trials it was found that the majority of successful cases (73%) responded to single injections. In some selected cases, however, multiple dosing at intervals of 15 to 90 minutes was carried out with successful outcome. The need for additional injections and the inte…

Warnings

WARNINGS HEMABATE Sterile Solution (carboprost tromethamine), like other potent oxytocic agents, should be used only with strict adherence to recommended dosages. HEMABATE should be used by medically trained personnel in a hospital which can provide immediate intensive care and acute surgical facilities. HEMABATE does not appear to directly affect the fetoplacental unit. Therefore, the possibility does exist that the previable fetus aborted by HEMABATE could exhibit transient life signs. HEMABATE is not indicated if the fetus in utero has reached the stage of viability. HEMABATE should not be considered a feticidal agent. Evidence from animal studies has suggested that certain other prostaglandins have some teratogenic potential. Although these studies do not indicate that HEMABATE is teratogenic, any pregnancy termination with HEMABATE that fails should be completed by some other means. This product contains benzyl alcohol. Benzyl alcohol has been reported to be associated with a fatal "Gasping Syndrome" in premature infants.

Contraindications

CONTRAINDICATIONS 1. Hypersensitivity (including anaphylaxis and angioedema) to HEMABATE Sterile Solution [ see ADVERSE REACTIONS, Post-marketing Experience ] 2. Acute pelvic inflammatory disease 3. Patients with active cardiac, pulmonary, renal or hepatic disease

Drug Interactions

Drug Interactions HEMABATE may augment the activity of other oxytocic agents. Concomitant use with other oxytocic agents is not recommended.

Adverse Reactions

ADVERSE REACTIONS The adverse effects of HEMABATE Sterile Solution are generally transient and reversible when therapy ends. The most frequent adverse reactions observed are related to its contractile effect on smooth muscle. In patients studied, approximately two-thirds experienced vomiting and diarrhea, approximately one-third had nausea, one-eighth had a temperature increase greater than 2° F, and one-fourteenth experienced flushing. The pretreatment or concurrent administration of antiemetic and antidiarrheal drugs decreases considerably the very high incidence of gastrointestinal effects common with all prostaglandins used for abortion. Their use should be considered an integral part of the management of patients undergoing abortion with HEMABATE. Of those patients experiencing a temperature elevation, approximately one-sixteenth had a clinical diagnosis of endometritis. The remaining temperature elevations returned to normal within several hours after the last injection. Adverse effects observed during the use of HEMABATE for abortion and for hemorrhage, not all of which are clearly drug related, in decreasing order of frequency include: Vomiting Nervousness Diarrhea Noseblee…

Frequently Asked Questions

What is Hemabate used for?

Hemabate contains carboprost tromethamine. It is a injection, solution taken intramuscular. Consult your doctor for specific uses.

Is Hemabate a controlled substance?

Hemabate is not classified as a controlled substance by the DEA.

What is the generic name for Hemabate?

The generic name for Hemabate is carboprost tromethamine. There are 12 other brand versions of carboprost tromethamine.

What is the NDC code for Hemabate 250 ug/mL?

The NDC (National Drug Code) for Hemabate 250 ug/mL is 0009-0856, listed by Pharmacia & Upjohn Company LLC.

Product NDC

0009-0856

Package NDC

0009-0856-05

Other Carboprost Brands

See all →

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)